紧张的微质细胞在阿尔茨海默病中转向黑暗的一面
Gilbert Di Paolo1, Joseph W Lewcock1
1Denali Therapeutics, 161 Oyster Point Boulevard, South San Francisco, CA 94080, USA.
Neuron
|February 20, 2025
概括
与衰老和神经退行相关的黑色微质细胞通过释放有毒脂质来积极推动这些疾病. 这一发现揭示了大脑衰老和疾病进展的关键机制.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 微质细胞是中枢神经系统的主要免疫细胞.
- 在衰老和神经退行性疾病中观察到一个独特的亚群",黑暗的微质细胞".
- 黑暗微质在疾病发病过程中的确切功能仍然在很大程度上是未知的.
研究的目的:
- 阐明暗微质在神经退行症中的功能性作用.
- 确定暗微质细胞对神经元损伤有所贡献的分子机制.
主要方法:
- 利用先进的成像技术在体内识别和描述黑暗的微质细胞.
- 在孤立的黑色微质上进行了转录和脂质组分析.
- 在疾病模型中使用遗传和药理干预来调节暗微质活性.
主要成果:
- 证实暗色微质细胞积极参与神经退行过程.
- 这些细胞分泌特定的有毒脂质,诱导神经元功能障碍和死亡.
- 抑制暗色微质活动或它们的脂质分泌改善了神经退行.
结论:
- 暗色微质细胞不仅仅是衰老的被动指标,而且是神经退行症的积极驱动因素.
- 黑色微质体对有毒脂质的分泌代表了一个关键的致病机制.
- 准暗色微质细胞或其脂质产物为神经退行性疾病提供了潜在的治疗策略.
相关概念视频
01:26Alzheimer's Disease: Overview
425
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
425
01:22Alzheimer's Disease: Treatment
149
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
149